From cancer to major infectious diseases, the science of Glycomics is an exciting new frontier in biomedical research. The Institute takes a multi-disciplinary approach to understand the role that carbohydrates (sugars) play in the biological processes of disease to create vaccines for prevention and drugs for treatment. While the human genome project was the great scientific accomplishment to end the 20th century, in the 21st century decoding the glycome is a new and promising frontier.
Founded in 2000 by Institute Director Professor Mark von Itzstein, who featured on the cover of Time Magazine as co-inventor of the world’s first anti-flu drug Zanamivir (Relenza®), the Institute boasts 200 leading biomedical researchers, including Professor Michael Good, who has vaccines for both Malaria and Strep A bacteria in human clinical trials. The Institute has secured more than $100 million in research funding to date.
The Institute works with leading national and international partners to translate its research, including a significant partnership in the world's largest commercial glycan array. It seeks to extend it's growing network of international partners and collaborators within the biotechnology and pharmaceutical private sector; investors; philanthropic agencies and leading research organisations.
Research tackles a variety of infectious diseases and cancers, including a range of mosquito-borne diseases, respiratory illnesses and childhood cancers.
- Cancer Glycomics
- Clinical Trials
- Computational Biology
- Drug and Vaccine Discovery & Development
- Glycomics Array & Other Enabling Technologies
- Infectious Diseases Research
- Medicinal Chemistry & Carbohydrate Synthesis
- Molecular Biophysics
- Structure-Based Drug Design